MoST Substudy 1: Single arm, open label, signal seeking, phase Ib/IIa trial of the CDK4/6 inhibitor palbociclib in patients with tumours with amplified D-type cyclins or CDK4 or inactivation of CDKN2A.

Trial Profile

MoST Substudy 1: Single arm, open label, signal seeking, phase Ib/IIa trial of the CDK4/6 inhibitor palbociclib in patients with tumours with amplified D-type cyclins or CDK4 or inactivation of CDKN2A.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Acronyms MoST Substudy 1
  • Most Recent Events

    • 02 Mar 2018 Planned End Date changed from 9 May 2017 to 31 Dec 2019.
    • 02 Mar 2018 Status changed from not yet recruiting to active, no longer recruiting.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top